CD19 and non-Hodgkin lymphoma: Studies have reported CD19 CAR‐T pharmacokinetics in patients with ALL and NHL, allowing scientists to acknowledge the associations between the characterization of the cellular kinetics of CD19 CAR‐T and the efficacy or safety of these modalities.17, 18